###begin article-title 0
Isolated Addison's disease is unlikely to be caused by mutations in MC2R, MRAP or STAR, three genes responsible for familial glucocorticoid deficiency
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease caused by ACTH resistance and leads to isolated glucocorticoid deficiency. Although FGD patients typically have normal mineralocorticoid secretion, subtle alterations in the renin-angiotensin-aldosterone axis have been reported in a subset of patients at presentation. Anecdotally, some patients with FGD have been initially diagnosed as having Addison's disease (AD), with implications for treatment and genetic counselling. Currently, mutations in three genes: the ACTH receptor (MC2R); the melanocortin 2 receptor accessory protein (MRAP); and the steroidogenic acute regulatory protein (STAR) are known to give rise to FGD types 1-3. We investigated a cohort of autoantibody-negative AD patients for mutations in these genes.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Forty patients with known AD without evidence of autoimmune disease were screened for mutations in MC2R, MRAP and STAR. In addition, patients were genotyped for the MC2R promoter polymorphism previously associated with reduced responsiveness to ACTH.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 58 65 <span type="species:ncbi:9606">patient</span>
No mutations in MC2R, MRAP or STAR were identified in any patient. The frequencies of the MC2R promoter polymorphism were similar to those reported in healthy controls.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 95 103 <span type="species:ncbi:9606">patients</span>
FGD does not appear to be underdiagnosed in the AD population. However, in approximately50% of patients with FGD, no genetic cause has yet been identified and it is possible that the other, as yet unidentified, genes giving rise to FGD may be implicated in AD.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 120 126 120 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1 bib2">(1, 2)</xref>
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">(3)</xref>
###xml 470 473 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">(1)</xref>
###xml 771 774 771 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">(4)</xref>
Primary adrenal failure is relatively rare with a prevalence of approximately five cases per 100 000 in Northern Europe (1, 2). The initial cases described by Addison in 1855 involved tuberculosis, adrenal malignancy and idiopathic adrenal fibrosis, which is now thought to be the first report of autoimmune adrenal disease (3). Currently, autoimmune Addison's disease (AAD) accounts for the majority of cases of primary adrenal failure in western countries (up to 94%) (1). AAD can occur either in conjunction with other autoimmune conditions (autoimmune polyendocrine syndromes), or in isolation. Isolated AAD with no other autoimmune clinical manifestations occurs in about 40% of cases, but positive autoantibodies have been shown to be present in up to 80% of these (4).
###end p 10
###begin p 11
Primary adrenal insufficiency (or antibody-negative AD) covers a broad spectrum of pathologies including malignant, infectious and genetic causes. Genetic causes range from autosomal or X-linked recessive conditions such as familial ACTH resistance syndromes (familial glucocorticoid deficiency (FGD), Triple A), congenital adrenal hyperplasia and adrenoleukodystrophy to mitochondrial disorders such as Kearns-Sayres syndrome.
###end p 11
###begin p 12
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">(5)</xref>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 540 546 540 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6 bib7">(6, 7)</xref>
###xml 584 588 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 707 710 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">(8)</xref>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
FGD (OMIM 202200) is an autosomal recessive condition characterised by ACTH resistance leading to isolated glucocorticoid deficiency with normal mineralocorticoid secretion. The syndrome was first described by Shepard et al. in 1959 in two siblings who had initially been diagnosed with AD (5). However, although patients with FGD have normal renin and aldosterone levels, subtle abnormalities of the renin-angiotensin axis are sometimes seen in this condition at diagnosis, most notably with nonsense mutations of the ACTH receptor (MC2R) (6, 7). In contrast, the recently described MC2R knockout mouse model demonstrates classical adrenal failure with both glucocorticoid and mineralocorticoid deficiency (8).
###end p 12
###begin p 13
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 136 139 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">(9)</xref>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">(10)</xref>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 330 338 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">(11)</xref>
###xml 492 496 492 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">(12)</xref>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 694 698 694 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 698 702 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">(13)</xref>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 1240 1243 1240 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">(5)</xref>
###xml 1281 1285 1281 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 1420 1424 1420 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 1429 1433 1429 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 1661 1665 1661 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 1667 1671 1667 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 1675 1679 1675 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 1760 1764 1760 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 98 105 <span type="species:ncbi:9606">patient</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
###xml 1574 1582 <span type="species:ncbi:9606">patients</span>
The first inactivating mutation of the MC2R (also known as the melanocortin type 2 receptor) in a patient with FGD was reported in 1993 (9), and subsequently more than 30 mutations in the MC2R have been found (10). In 2004, a polymorphism in the MC2R promoter at position 2 was described as having decreased response to ACTH both in vitro and in normal human subjects following i.v. ACTH infusion (11). More recently, mutations in a novel gene, the melanocortin 2 receptor accessory protein (MRAP), which is involved in trafficking MC2R to the plasma membrane, have been described in FGD (12). In 2009, Metherell et al. reported that a proportion of patients with FGD (5-10%) have mutations in STAR(13). STAR mutations usually give rise to a severe form of adrenal insufficiency known as lipoid congenital adrenal hyperplasia (LCAH; OMIM 201701), leading to both mineralocorticoid and glucocorticoid deficiency. Mutations in these three genes lead to FGD types 1, 2 and 3 respectively and account for just over 50% of all known clinical cases of FGD. Furthermore, there are reports of patients initially diagnosed with AD subsequently having their diagnosis refined to FGD, allowing them to omit their mineralocorticoid replacement therapy (5). Of note, two families found to have STAR mutations leading to adrenal failure were initially diagnosed with non-AAD. Having noted that there appear to be certain mutations in MC2R and STAR causing adrenal failure with both mineralocorticoid and glucocorticoid abnormalities, we investigated here the possibility that a subset of patients with isolated AD without evidence of autoimmune disease may have mutations in MC2R, MRAP or STAR. In addition, we screened the AD cohort for possible increased frequency of the MC2R promoter polymorphism associated with reduced responsiveness to ACTH.
###end p 13
###begin title 14
Subjects and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">(14)</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
###xml 764 772 <span type="species:ncbi:9606">Patients</span>
###xml 837 844 <span type="species:ncbi:9606">patient</span>
Forty patients (17 males and 23 females) with isolated AD were identified from a previously described cohort of patients studied in the north-east of England (14). The mean age of diagnosis was 36.5 years (range 8-79 years). All patients demonstrated a peak cortisol response of <550 nmol/l following a short synacthen test (250 mug synthetic ACTH administered i.m). All patients had a diagnosis of primary adrenal failure (secondary adrenal failure, infiltrative and infective causes were excluded). All patients with evidence of autoimmune disease or polyendocrinopathy (positive adrenal autoantibody screen by immunofluorescence or other organ system affected, e.g. thyroid dysfunction, vitiligo, type 1 diabetes mellitus and pernicious anaemia) were excluded. Patients with any family history of autoimmune disease were excluded. No patient had formal investigation of the renin-angiotensin axis, although none were known to have maintained normal mineralocorticoid secretion. There was one familial case of AD in the cohort (mother diagnosed at the age of 28 years and her son diagnosed at the age of 8).
###end p 16
###begin title 17
DNA extraction
###end title 17
###begin p 18
Genomic DNA was extracted from whole blood using the Nucleon BACC DNA extraction kit according to the manufacturer's instructions (GE Healthcare, Buckinghamshire, UK).
###end p 18
###begin title 19
Sequencing
###end title 19
###begin p 20
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 228 239 228 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6 bib13 bib15">(6, 13, 15)</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
MC2R has a single-coding exon. It has previously been reported that the majority of the mutations in MRAP in FGD patients are in exon 3. Exon 5 of STAR is where all mutations in non-classical LCAH and/or FGD have been described (6, 13, 15), whereas mutations found in other exons in this gene cause the classical LCAH phenotype.
###end p 20
###begin p 21
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 174 182 174 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12 bib13">(12, 13)</xref>
PCR was carried out using published primers directed to intronic sequences to cover the coding exon of MC2R, exon 3 of MRAP and exons 5 and 6 of STAR in the entire AD cohort (12, 13). Cycling conditions were 95 degreesC for 5 min (1 cycle); 95 degreesC for 30 s, 55 degreesC for 30 s and 72 degreesC for 30 s (30 cycles); and 72 degreesC for 5 min. PCR products were visualized on 1% agarose gel, and PCR fragments were sequenced using the ABI Prism Big Dye Sequencing kit and an ABI 3700 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions.
###end p 21
###begin title 22
Genotyping
###end title 22
###begin p 23
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">(11)</xref>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sac1</italic>
PCR was carried using previously published primers around the -2 MC2R promoter polymorphism (11). PCR products were digested with Sac1 giving three possible genotypes (CTC/CTC homozygote, CTC/CCC heterozygote and CCC/CCC homozygote), when run on a 2% agarose gel as previously reported. To confirm the accuracy of restriction enzyme digestion, conventional sequencing of three apparent homozygotes for both alleles and three heterozygotes was carried out as above.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRAP</italic>
###xml 58 65 <span type="species:ncbi:9606">patient</span>
No mutations in MC2R, MRAP or STAR were identified in any patient. There were no single nucleotide polymorphisms (SNPs) identified in the MC2R coding exon, but a number of individuals had a previously reported intronic SNP (rs2254251) downstream of exon 3 of MRAP.
###end p 25
###begin p 26
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 350 353 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 353 354 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 522 526 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">(11)</xref>
###xml 69 76 <span type="species:ncbi:9606">patient</span>
For the promoter polymorphism in MC2R, the C allele frequency in our patient population was 0.112 (9/80), which is comparable with the HapMap CEPH SNP database C allele frequency of 0.117. In the AD cohort studied, frequencies of MC2R promoter polymorphism were not significantly different to previously reported frequencies in normal controls using chi2 test with 2 d.f.: CTC/CTC 71.0% (80.2%); CTC/CCC 26.4% (19.0%) and CCC/CCC 2.6% (0.8%); figures given in parentheses describe reported frequencies in healthy controls (11). The population studied was in Hardy-Weinberg equilibrium.
###end p 26
###begin title 27
Discussion
###end title 27
###begin p 28
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAR</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MC2R</italic>
###xml 731 743 731 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11 bib16 bib17">(11, 16, 17)</xref>
###xml 1313 1317 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">(18)</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 1027 1035 <span type="species:ncbi:9606">patients</span>
###xml 1278 1286 <span type="species:ncbi:9606">patients</span>
AD is a common cause of adrenal failure in adults. In our cohort of FGD patients and other reported patients with non-classical LCAH, there are several reports of family members diagnosed initially with Addison's disease or with late onset of symptoms of glucocorticoid deficiency who have subsequently been found to have mutations in MC2R or STAR with alterations in their renin-angiotensin-aldosterone axis. However, our results indicate that FGD is not being underdiagnosed within the wider AD population in the UK. Furthermore, there does not appear to be any significant increase in the MC2R promoter polymorphism consistent with reduced responsiveness to ACTH, consistent with other Caucasian populations previously reported (11, 16, 17), although we accept that a detailed analysis of a local control population would be desirable. However, it may be that in other regions, mutation screening for FGD is not considered perhaps because of an atypical biochemical profile or resource considerations, and consequently such patients are being diagnosed as having antibody negative AD. Nevertheless, mutations in these genes account for only just over 50% of cases of FGD. It is known that there are several further loci involved in FGD and there is phenotypic variability in patients with FGD of unknown cause (18). It is possible that as yet unidentified gene(s) for FGD could account for familial cases of non-AAD.
###end p 28
###begin title 29
Declaration of interest
###end title 29
###begin p 30
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
###end p 30
###begin title 31
Funding
###end title 31
###begin p 32
R P Dias is a Clinical Research Fellow funded by the Medical Research Council.
###end p 32
###begin title 33
References
###end title 33
###begin article-title 34
Eighty-six cases of Addison's disease
###end article-title 34
###begin article-title 35
Addison's disease - clinical studies. A report of 108 cases
###end article-title 35
###begin article-title 36
Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction
###end article-title 36
###begin article-title 37
Familial Addison's disease; case reports of two sisters with corticoid deficiency unassociated with hypoaldosteronism
###end article-title 37
###begin article-title 38
###xml 69 77 <span type="species:ncbi:9606">children</span>
Homozygous nonsense and frameshift mutations of the ACTH receptor in children with familial glucocorticoid deficiency are not associated with long-term mineralocorticoid deficiency
###end article-title 38
###begin article-title 39
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia
###end article-title 39
###begin article-title 40
Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis
###end article-title 40
###begin article-title 41
Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor
###end article-title 41
###begin article-title 42
Inherited ACTH insensitivity illuminates the mechanisms of ACTH action
###end article-title 42
###begin article-title 43
Characterization of an adrenocorticotropin (ACTH) receptor promoter polymorphism leading to decreased adrenal responsiveness to ACTH
###end article-title 43
###begin article-title 44
Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2
###end article-title 44
###begin article-title 45
Non-classic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency
###end article-title 45
###begin article-title 46
Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease
###end article-title 46
###begin article-title 47
Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia
###end article-title 47
###begin article-title 48
###xml 137 145 <span type="species:ncbi:9606">children</span>
ACTH receptor promoter polymorphism associates with severity of premature adrenarche and modulates hypothalamo-pituitary-adrenal axis in children
###end article-title 48
###begin article-title 49
Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction
###end article-title 49
###begin article-title 50
A novel variant of familial glucocorticoid deficiency prevalent among the Irish Traveler population
###end article-title 50

